Health Canada has approved Svemia, the nation's first generic semaglutide injection specifically authorized for chronic weight management. The drug, manufactured by Canadian pharmaceutical company Apotex, is a generic equivalent to Novo Nordisk’s Wegovy.
Regulators cleared the once-weekly injection for individuals aged 12 and older as a supplement to a reduced-calorie diet and increased physical activity. While two other generic semaglutide products were approved earlier this year for Type 2 diabetes, Svemia marks the first entry targeting the weight loss market.
The government body is currently reviewing six additional generic semaglutide submissions, signaling a wave of new approvals in the coming months.